Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model.

Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model.

Global control of tuberculosis (TB), an infectious disease that claims nearly 2 million lives annually, is hindered by the long duration of chemotherapy required for curative treatment. Lack of adherence to this intense treatment regimen leads to poor patient outcomes, development of new or addition...

Full description

Bibliographic Details
Main Authors: Mamoudou Maiga, Nisheeth Agarwal, Nicole C Ammerman, Radhika Gupta, Haidan Guo, Marama C Maiga, Shichun Lun, William R Bishai
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3272040?pdf=render

Internet

http://europepmc.org/articles/PMC3272040?pdf=render

Similar Items